Results 31 to 40 of about 17,658 (223)
Thoracic Cancer, 2020 Background Previous trials have suggested that elderly patients with non‐small‐cell lung cancer (NSCLC) could benefit from nanoparticle albumin‐bound paclitaxel (nab‐paclitaxel). Real‐world data on the elderly Chinese population are lacking.
Shuhang Wang +12 more
doaj +1 more source
Nab-Paclitaxel plus gemcitabine in patients with metastatic pancreatic adenocarcinoma: experience of use [PDF]
Farmacia Hospitalaria, 2015 Objective: To evaluate the results obtained with the combined use of nab-paclitaxel and gemcitabine in the treatment of patients with metastatic pancreatic adenocarcinoma. Materials and methods: Retrospective observational study.
Elena Ferris Villanueva +5 more
doaj +1 more source
Translational Oncology, 2018 Esophageal adenocarcinoma (EAC) is the fastest growing cancer in the western world and the overall 5 year survival rate of EAC is below 20%. Most patients with EAC present with locally advanced or widespread metastatic disease, where current treatment is
Md Sazzad Hassan +6 more
doaj +1 more source
Dermatology Practical & Conceptual, 2015 Background: Taxanes [paclitaxel, nab-paclitaxel (Abraxane, Celgene Corp, USA), and docetaxel]—used in the treatment of lung, breast, and head and neck cancers—have been associated with cutaneous adverse effects, including photodermatoses.
Bryce D. Beutler, Philip R. Cohen
doaj +1 more source
Journal of Experimental & Clinical Cancer Research, 2022 Background Chemoresistance is a main obstacle in gastric cancer (GC) treatment, but its molecular mechanism still needs to be elucidated. Here, we aim to reveal the underlying mechanisms of nanoparticle albumin-bound paclitaxel (nab-paclitaxel ...
Mengxuan Zhu +8 more
doaj +1 more source
nab-Paclitaxel dose and schedule in breast cancer [PDF]
Breast Cancer Research, 2015 Abstractnab-Paclitaxel is approved for the treatment of metastatic breast cancer on an every-3-week schedule based on positive findings from a pivotal phase III trial in which nab-paclitaxel 260 mg/m2 every 3 weeks was superior to solvent-based paclitaxel 175 mg/m2 every 3 weeks for the primary endpoint of overall response rate (33 % vs 19 %; P = 0.001)
openaire +3 more sources
First-Line Treatment with Carboplatin plus nab-Paclitaxel and Maintenance Monotherapy with nab-Paclitaxel for a Thymic Carcinoma: A Case Report [PDF]
Case Reports in Oncology, 2017 Thymic carcinomas are rare malignant tumors, located in the anterior mediastinum. For the treatment of these carcinomas, several chemotherapy regimens have been suggested, including carboplatin plus paclitaxel. However, because of the rarity of these tumors, the standard chemotherapy regimen has not yet been established.
Kunihiko Funaishi +7 more
openaire +3 more sources
Качественная клиническая практика, 2020 Objective. To determine the pharmacoeconomical feasibility of using a combination of atezolizumab + nab-paclitaxel in the 1st line of therapy for locally advanced or metastatic triple negative breast cancer (TNBC) in adult PDL1 positive patients in the ...
A S Kolbin +4 more
doaj +1 more source
nab-Paclitaxel for the treatment of pancreatic cancer.
Cancer management and research, 2017 Nanoparticle albumin-bound paclitaxel (nab-P) plus gemcitabine (Gem) became a standard treatment option for metastatic pancreatic cancer (MPC) following positive results from a global phase III trial (MPACT). A large number of studies have now published results on the use of nab-P/Gem to treat advanced and early-stage disease, warranting a ...
openaire +4 more sources
Stromal disrupting effects of nab-paclitaxel in pancreatic cancer [PDF]
British Journal of Cancer, 2013 Nab-paclitaxel and gemcitabine have demonstrated a survival benefit over gemcitabine alone in advanced pancreatic cancer (PDA). This study aimed to investigate the clinical, biological, and imaging effects of the regimen in patients with operable PDA.Patients with operable PDA received two cycles of nab-paclitaxel and gemcitabine before surgical ...
Alvarez, R +16 more
openaire +3 more sources